Crosser Enters The Right Arterial Lumen (CENTRAL)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if the CROSSER CTO Recanalization System can facilitate the successful crossing of Chronic Total Occlusions in the Central lumen of the Superficial Femoral Artery (SFA). A Chronic Total Occlusion (CTO) is defined as 100% narrowing of the artery, with no angiographically detectable antegrade blood flow, and the assessment that the lesion has been in existence for a minimum of 30 days. This study will enroll up to 100 patients at up to 8 clinical sites. The CROSSER CTO Recanalization System was cleared for commercialization by the US Food & Drug Administration. This study also involves an imaging device called the IVUS (Intravascular Ultrasound Imaging) catheter. This device has been cleared for commercialization by the US Food and Drug Administration and will be studied for its cleared intended use. The IVUS catheter is used to generate real-time images of the artery, which will allow for evaluation of the artery after the occlusion is crossed. This is a post-market registry.
| Condition | Intervention |
|---|---|
|
Chronic Total Occlusion of Artery of the Extremities |
Device: 1. CROSSER System |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Crosser Enters The Right Arterial Lumen |
- Crosser navigates through the central lumen of the artery [ Time Frame: At time of procedure (day 0) ] [ Designated as safety issue: No ]Successful navigation of the CROSSER CTO Recanalization Catheter in the central lumen of the artery as confirmed by Intravascular Ultrasound (IVUS) following recanalization
- Technical Success - crossing the CTO into the true distal lumen [ Time Frame: At time of procedure (Day 0) ] [ Designated as safety issue: No ]The ability to facilitate crossing the CTO into the true distal lumen with the CROSSER Catheter and/or any conventional guidewire after use of the CROSSER.
- Procedural Success - Technical success plus residual stenosis < 50% and improved flow [ Time Frame: Time of Procedure (Day 0) ] [ Designated as safety issue: No ]Achievement of Technical Success plus a residual stenosis <50%, and improved flow verified angiographically, at the conclusion of the procedure.
- Clinical Success - freedom from limb loss and repeat revascularization [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]Clinical Success - freedom from limb loss, and repeat revascularization (bypass surgery, or PTA) from index hospitalization through 6 moth follow-up
| Enrollment: | 100 |
| Study Start Date: | February 2010 |
| Study Completion Date: | August 2012 |
| Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| CROSSER |
Device: 1. CROSSER System
The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient must have objective evidence of lower extremity ischemia and scheduled to undergo an endovascular recanalization.
- Occluded artery must be the native superficial femoral artery.
- Patient must have a totally occlusive lesion classified angiographically as absolute (100% occlusion with no flow).
- Patient's target vessel occlusion length is ≤ 30 cm.
- Patient's reference vessel diameter is greater than or equal to 3.0mm.
- Patient must be an acceptable candidate for PTA, peripheral artery bypass surgery or peripheral artery stent implantation.
- Female patients of child bearing potential must have a negative pregnancy test within 72 hours prior to the study procedure.
- Patient or guardian must have been informed of the nature of the study, agree to its provisions, and provide written informed consent.
- Patient is ≥ 18 years of age.
Exclusion Criteria:
- Patient has hypersensitivity or contraindication to aspirin, heparin or radiographic contrast agents which cannot be adequately pre-medicated.
- The patient requires immediate treatment in more than one occluded vessel, in any combination of grafts or native vessels.
- Patient's occlusion is a flush occlusion initiating less than 2cm from the ostium.
- Patient has planned infrainguinal intervention scheduled within 30 days after index procedure.
- The patient is currently participating in another investigational drug or device trial that may conflict with study data collection and has not completed the entire follow-up period.
- Patient has no collateral flow distal to the occlusion.
- Patient's target occlusion has a dissection that occurred within the past 60 days caused by a guidewire attempt.
- Patient has a history of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency.
- Patient suffered recent (within the past 6 months) stroke or transient ischemic neurological attack (TIA).
- Patient suffered recent (within the past 6 months) significant gastrointestinal (GI) bleeding.
- Patient has other medical illnesses (i.e., cancer or congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with life-expectancy less than 1 year.
Contacts and Locations| United States, District of Columbia | |
| Washington Hospital Center | |
| Washington, District of Columbia, United States, 20010 | |
| United States, Iowa | |
| Iowa Methodist Medical Center | |
| Des Moines, Iowa, United States, 50325 | |
| United States, Michigan | |
| St. John Hospital and Medical Center | |
| Detroit, Michigan, United States, 48236 | |
| Metro Health Hospital | |
| Wyoming, Michigan, United States, 49519 | |
| United States, Minnesota | |
| Mercy Heart and Vascular Center | |
| Coon Rapids, Minnesota, United States, 55433 | |
| United States, New York | |
| Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| United States, Ohio | |
| The Christ Hospital | |
| Cincinnati, Ohio, United States, 45243 | |
| United States, Tennessee | |
| Memphis Heart Clinic | |
| Memphis, Tennessee, United States, 38120 | |
| Principal Investigator: | Thomas P. Davis, MD | St. John Hospital and Medical Center |
More Information
No publications provided
| Responsible Party: | C. R. Bard |
| ClinicalTrials.gov Identifier: | NCT01205386 History of Changes |
| Other Study ID Numbers: | CR1055-01 |
| Study First Received: | April 26, 2010 |
| Last Updated: | September 14, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by C. R. Bard:
|
CTO peripheral artery occlusive disease PAOD SFA superficial femoral artery |
Additional relevant MeSH terms:
|
Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013